Tango Therapeutics said on October 23, 2026, that its vopimetostat trial recorded an 82% objective response rate in 22 evaluable patients with previously treated pancreatic cancer who received the drug with daraxonrasib. The company plans to move the combination into a randomized, front-line Phase 3 study in the first half of 2027 following discussions with the U.S. Food and Drug Administration.
Key Takeaways
- The pancreatic cancer combination produced responses in 18 of 22 evaluable patients; median progression-free survival had not been reached.
- Safety differed by dose: the lower vopimetostat dose was generally tolerated, while the higher dose produced dose-limiting toxicities.
- The planned Phase 3 trial will compare the combination with standard chemotherapy in previously untreated patients with MTAP-deleted pancreatic cancer.
Table of Contents
- Vopimetostat trial results show activity in previously treated patients
- Safety findings distinguish the two dose levels
- The treatment targets a genetic vulnerability
- Phase 3 would move the combination into front-line treatment
- Conclusion
Vopimetostat trial results show activity in previously treated patients
The Phase 1/2 findings cover patients with metastatic pancreatic ductal adenocarcinoma, or PDAC, whose tumors had both MTAP deletion and a RAS mutation. At the August 20, 2026, data cutoff, 22 patients were evaluable for efficacy, including 13 receiving the combination as their third line of treatment.
Eighteen patients had partial responses. Eleven responses were confirmed at the cutoff, while seven were unconfirmed; Tango said all seven were subsequently confirmed. Median follow-up was 7.1 months, ranging from 3.3 to 12.5 months.
The reported nine-month progression-free survival rate was 88%, and the disease control rate was 100%. Median progression-free survival had not yet been reached, so the study does not yet establish the median duration patients can remain alive without disease progression.
These are early findings from a small, open-label study, not a randomized comparison with chemotherapy. They therefore do not establish that the combination is superior to existing treatment. Tango is presenting the results at the European Society for Medical Oncology Congress in Madrid on October 23–27.
| Item | Details |
|---|---|
| Planned Phase 3 allocation | Patients randomized 1:1 between the combination and standard-of-care chemotherapy. |
| Combination dosing | Vopimetostat 200 mg once daily plus daraxonrasib 100 mg once daily. |
| Dual primary endpoints | Objective response rate and progression-free survival. |
| Key secondary endpoint | Overall survival. |
Safety findings distinguish the two dose levels
Among 25 safety-evaluable pancreatic cancer patients receiving vopimetostat 200 mg daily with daraxonrasib 100 mg daily, there were no dose-limiting toxicities, treatment-related withdrawals or Grade 4 or 5 treatment-related adverse events. Grade 3 treatment-related events occurred in 40%, and 20% required dose reductions.
The most common treatment-related events at that dose were stomatitis, rash and diarrhea, all Grade 1 or 2. The higher vopimetostat dose of 250 mg was not well tolerated: three dose-limiting toxicities occurred in two of four safety-evaluable patients.
A separate vopimetostat combination with zoldonrasib produced a 54% response rate among 35 evaluable pancreatic cancer patients with MTAP deletion and a KRAS G12D mutation. Among 39 safety-evaluable patients, there were no dose-limiting toxicities or treatment-related withdrawals, although Grade 3 events occurred in 28% and one Grade 4 event was reported. The separate cohorts do not provide a head-to-head comparison of the two combinations.
The treatment targets a genetic vulnerability
Vopimetostat is an investigational oral PRMT5 inhibitor. Tango's explanation of MTAP-selective PRMT5 inhibition describes how loss of MTAP creates a vulnerability that can make cancer cells more susceptible to PRMT5 inhibition than normal cells. This is the biological rationale for selecting patients by their tumor's genetic characteristics, rather than treating pancreatic cancer as a single uniform population.
Daraxonrasib and zoldonrasib are Revolution Medicines' RAS(ON) inhibitors. The ongoing trial is testing their combinations with vopimetostat in selected pancreatic and non-small cell lung cancers; the newly reported findings do not establish effectiveness across all patients with either disease.
Phase 3 would move the combination into front-line treatment
Tango plans a global registrational study in patients with previously untreated MTAP-deleted PDAC. That represents a change in treatment setting from the previously treated patients underlying the latest pancreatic cancer results.
The proposed study would use the lower vopimetostat dose and compare the combination directly with standard-of-care chemotherapy. Its planned design is outlined below.
Tango also intends to discuss a possible second-line approval pathway with regulators. Neither those discussions nor the planned Phase 3 study amount to regulatory approval of the combination.
Conclusion
The next planned milestone is initiation of the randomized Phase 3 study in the first half of 2027. That trial would test whether the early response and disease-control findings translate into benefit against standard chemotherapy in front-line treatment.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
